1. Considered and approved Unaudited Standalone Financial Results for the Quarter ended 30th June, 2025 along with the Limited review report; 2. Other Agenda in the attached file.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Choksi Laboratories' Board approved unaudited standalone financial results for Q1 FY26 (quarter ended June 30, 2025). Revenue from operations rose to ₹1,139.95 Lacs from ₹1,073.64 Lacs YoY (up ~6.2%). Profit before tax more than doubled to ₹125.94 Lacs from ₹61.50 Lacs, and net profit surged to ₹92.13 Lacs from ₹38.50 Lacs (up ~139% YoY), reflecting strong margin expansion. The auditor (Prateek Jain & Co.) issued a clean limited review report with no qualifications. The Board also approved the 32nd AGM for September 16, 2025, re-appointed Mr. Vyangesh Choksi as Whole Time Director, and appointed M/s Surabhi Agrawal & Associates as Secretarial Auditor for five years (FY26–FY30).
Sharp jump in profitability signals improving operating leverage and cost efficiency, which is positive for shareholders despite modest revenue growth. Routine governance approvals (auditor re-appointments, director re-appointment, AGM scheduling) carry no material price impact on their own.